Technology & Data Science for Enhanced Patient Care


Learning Center

Access additional learning opportunities.


Help Us Reach Our Educational Support Goal of $40,000
Educational Travel Grants supported in part by:

Video Viewing Request

Video loading. Please wait...

How to Avoid a Bone Marrow Biopsy when Monitoring Minimum Residual Disease in Multiple Myeloma: Hope for the Future!
H. Robert Bergen, III
Mayo Clinic
[email protected]

Therapeutic effectiveness in multiple myeloma (MM) currently requires monitoring the relevant myeloma cells in a bone marrow sample. Because these plasma cell clones are producing a clonal antibody we sought to identify the antibody the clone was producing directly. Utilizing blood plasma where the M-protein is >0.8g/dL we have been able to identify unique tryptic peptides corresponding to immunoglobulin light chain variable regions belonging to each patients clone. Subsequent blood samples are utilized to measure MRD and the target peptide corresponding to each patients clone is monitored.

Presented at MSACL 2016 US